J
Jens Panse
Researcher at RWTH Aachen University
Publications - 124
Citations - 2688
Jens Panse is an academic researcher from RWTH Aachen University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 20, co-authored 83 publications receiving 1663 citations. Previous affiliations of Jens Panse include Huntsman Cancer Institute & Cambium Learning Group.
Papers
More filters
Journal ArticleDOI
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Andrés José Maria Ferreri,Kate Cwynarski,Elisa Jacobsen Pulczynski,Maurilio Ponzoni,Martina Deckert,Letterio S. Politi,Valter Torri,Christopher P. Fox,Paul La Rosée,Elisabeth Schorb,Achille Ambrosetti,Alexander Röth,Claire Hemmaway,Angela Ferrari,Kim Linton,Roberta Rudà,Mascha Binder,Tobias Pukrop,Monica Balzarotti,Alberto Fabbri,Peter Johnson,Jette Sønderskov Gørløv,Georg Hess,Jens Panse,Francesco Pisani,Alessandra Tucci,Stephan Stilgenbauer,Bernd Hertenstein,Ulrich Keller,Stefan W. Krause,Alessandro Levis,Hans J. Schmoll,Franco Cavalli,Jürgen Finke,Michele Reni,Emanuele Zucca,Gerald Illerhaus +36 more
TL;DR: The IELSG32 trial provides a high level of evidence supporting the use of MATRix combination as the new standard chemoimmunotherapy for patients aged up to 70 years with newly diagnosed primary CNS lymphoma and as the control group for future randomised trials.
Journal ArticleDOI
Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Sabine Mousset,Dieter Buchheidt,Werner J. Heinz,Markus Ruhnke,Oliver A. Cornely,Gerlinde Egerer,William Krüger,Hartmut Link,Silke Neumann,Helmut Ostermann,Jens Panse,Olaf Penack,Christina Rieger,Martin Schmidt-Hieber,Gerda Silling,Thomas Südhoff,Andrew J. Ullmann,Hans-Heinrich Wolf,Georg Maschmeyer,Angelika Böhme +19 more
TL;DR: The Infectious Diseases Working Party of the German Society of Hematology and Oncology here presents its 2008 recommendations discussing the dos and do-nots, as well as the problems and possible solutions, of evidence criteria selection.
Journal ArticleDOI
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
Andrés José Maria Ferreri,Kate Cwynarski,Elisa Jacobsen Pulczynski,Christopher P. Fox,Elisabeth Schorb,Paul La Rosée,Mascha Binder,Alberto Fabbri,Valter Torri,Eleonora Minacapelli,Monica Falautano,Fiorella Ilariucci,Achille Ambrosetti,Alexander Röth,Claire Hemmaway,Peter Johnson,Kim Linton,Tobias Pukrop,Jette Sønderskov Gørløv,Monica Balzarotti,Georg Hess,Ulrich Keller,Stephan Stilgenbauer,Jens Panse,Alessandra Tucci,Lorella Orsucci,Francesco Pisani,Alessandro Levis,Stefan W. Krause,Hans J. Schmoll,Bernd Hertenstein,Mathias J. Rummel,Jeffery Smith,Michael Pfreundschuh,Giuseppina Cabras,Francesco Angrilli,Maurilio Ponzoni,Martina Deckert,Letterio S. Politi,Juergen Finke,Michele Reni,Franco Cavalli,Emanuele Zucca,Gerald Illerhaus +43 more
TL;DR: The results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT) as an alternative to whole-brain radiotherapy (WBRT) as consolidation after high-dose-methotrexate-based chemoimmunotherapy were reported.
Journal ArticleDOI
Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Sibylle C. Mellinghoff,Jens Panse,Nael Alakel,Gerhard Behre,Dieter Buchheidt,Maximilian Christopeit,Justin Hasenkamp,Michael G. Kiehl,Michael Koldehoff,Stefan W. Krause,Nicola Lehners,Marie von Lilienfeld-Toal,Annika Y Löhnert,Georg Maschmeyer,Daniel Teschner,Andrew J. Ullmann,Olaf Penack,Markus Ruhnke,Karin Mayer,Helmut Ostermann,Hans-H. Wolf,Oliver A. Cornely +21 more
TL;DR: Prophylaxis should be performed with posaconazole delayed release tablets during remission induction chemotherapy for AML and MDS and can be used when the oral route is contraindicated or not feasible, as well as in cases of clinical failure such as breakthrough IFI.
Journal ArticleDOI
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Peter Hillmen,Jeff Szer,Ilene C. Weitz,Alexander Röth,Britta Höchsmann,Jens Panse,Kensuke Usuki,Morag Griffin,Jean-Jacques Kiladjian,Carlos M. de Castro,Hisakazu Nishimori,Lisa Tan,Mohamed Hamdani,Pascal Deschatelets,Cedric G. Francois,Federico Grossi,Temitayo Ajayi,Antonio M. Risitano,Régis Peffault de La Tour +18 more
TL;DR: Pegcetacoplan, a pegylated peptide targeting proximal complement protein C3, potentially inhibits both intravascular and extravascular hemolysis as discussed by the authors.